Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 9Thoracic 5Genitourinary 3Dermatologic 3Sarcoma 2Head & Neck 2Breast 2Other solid neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Carcinoma, Renal Cell 62Prostatic Neoplasms 35Kidney Neoplasms 18Carcinoma, Transitional Cell 17Melanoma 15Urinary Bladder Neoplasms 14Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 12Clear-cell metastatic renal cell carcinoma 11Colorectal Neoplasms 9Neoplasms 8Carcinoma, Hepatocellular 8Squamous Cell Carcinoma of Head and Neck 7Triple Negative Breast Neoplasms 6Ovarian Neoplasms 6Lung Neoplasms 6Uterine Cervical Neoplasms 5Stomach Neoplasms 5Pancreatic Neoplasms 5Urogenital Neoplasms 4Small Cell Lung Carcinoma 4Endometrial Neoplasms 4Carcinoma, Merkel Cell 4Urethral Neoplasms 3Penile Neoplasms 3Neuroblastoma 3Liver Neoplasms 3Brain Neoplasms 3Wilms Tumor 2Ureteral Neoplasms 2

Interventions

pembrolizumab 6Sorafenib 4Filgrastim 4Carboplatin 4Thiotepa 3Radiotherapy 3Psychiatric Rehabilitation 3Nivolumab 3Ipilimumab 3Cyclophosphamide 3sargramostim 2ixabepilone 2fludarabine 2Temozolomide 2Sirolimus 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Gene Expression Profiling 2Etoposide 2Drug Therapy 2Counseling 2Busulfan 2Bupropion 2Blood Specimen Collection 2Biopsy 2vofatamab 1utomilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Liver Neoplasms × Ipilimumab × Genitourinary × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT03752398 2024-07-05

DUET-3

Xencor, Inc.

Phase 1 Completed
198 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04311710 2023-02-24

CheckMate 76U

Bristol-Myers Squibb

Phase 1 Terminated
21 enrolled
DermatologicGastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡